6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2023

Commission File Number: 001-37384

GALAPAGOS NV (Translation of registrant's name into English)

Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ]      Form 40-F [   ]

The information contained in this Report on Form 6-K, including Exhibit 99.1, except for the quotes of Dr. Paul Stoffels and Thad Huston, included in Exhibit 99.1, is hereby incorporated by reference into the Company's Registration Statements on Form S-8 (File Nos. 333-204567, 333-208697, 333-211834, 333-215783, 333-218160, 333-225263, 333-231765, 333-249416, 333-260500, and 333-268756).

On June 15, 2023, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

(c) Exhibit 99.1. Press release dated June 15, 2023

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EdgarFiling

EXHIBIT 99.1

Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer

Mechelen, Belgium; 15 June 2023, 22:01 CET ; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced theappointment of T had Huston as Chief Financial Officer (C F O) and Chief Operating Officer (C O O) as per 1 July 2023 . Mr. Huston will be a member of the Executive Committee of Galapagos and will join Galapagos fromKite, a Gilead C ompany (NASDAQ: GILD) . He brings 30 years of globalfinance and operational experience in healthcare with an excellent track record of driving business transformation and innovation.

“On behalf of the Board of Directors and management of Galapagos, I extend a warm welcome to Thad. Thad is a widely recognized leader with a strong international network. Having spent three decades in the healthcare sector, he brings with him a wealth of experience and deep financial and operational know-how,” said Dr. Paul Stoffels^1^, CEO and Chairman of Galapagos. “We are convinced that Thad’s strategic and operational expertise, including in cell therapy, is an excellent fit for our company as we continue to execute on our R&D and business development strategy in our focus areas of immunology and oncology.”

Thad Huston is currently Global Head of Finance and Corporate Operations at Kite, the global leader in cell therapy. Before Kite, Thad served as CFO of LivaNova (NASDAQ: LIVN), a publicly listed medical devices company focused on neuromodulation with presence in more than 100 countries. Prior to that role, he spent over 25 years at Johnson & Johnson (J&J) (NYSE: JNJ) where he held senior financial roles at various J&J locations in the US, China, Belgium, Russia, and Hungary. During his tenure at J&J, he helped establish the R&D innovation model and played a key role in accelerating the product pipeline through focused growth strategies, investments in innovation, business development and streamlined productivity.

“I am very excited to join Galapagos and to work with Paul and the team to realize the company’s full potential,” added Thad Huston. “With its growing pipeline in oncology and immunology, a European commercial infrastructure and a robust balance sheet, I strongly believe that Galapagos has the fundamentals in place to deliver on its mission to transform the lives of patients across the globe, while creating value for its stakeholders.”

This press release contains inside information within the meaning of Regulation (EU) No 596/2014 of the European Parliament andof the Council of 16 April 2014 on market abuse (market abuse regulation).

About Galapagos Galapagos is a fully integrated biotechnology company united around a single purpose: to transform patient outcomes through life-changing science and innovation for more years of life and quality of life. We focus on the key therapeutic areas of immunology and oncology, where we have developed a deep scientific expertise in multiple drug modalities, including small molecules and cell therapies. Our portfolio comprises discovery through to commercialized programs and our first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. For additional information, please visit www.glpg.com or follow us on LinkedIn or Twitter.

Contacts

Forward-looking statements This press release includes forward-looking statements within the meaning of thePrivate Securities Litigation Reform Act of 1995, as amended. These statements are often, but are not always, made through the use ofwords or phrases such as “ongoing,” “will,” and “may” as well similar expressions. Forward-lookingstatements contained herein include, but are not limited to, statements regarding the announced leadership transition and changes in ourExecutive Committee and key personnel. These forward-looking statements are subject to risks, uncertainties and other factors that couldcause actual results to differ materially from those referred to in the forward-looking statements and, therefore, the reader shouldnot place undue reliance on them. These risks, uncertainties and other factors include, without limitation, the possibility that Galapagoswill encounter challenges retaining or attracting talent, that our leadership transition may be disruptive to our business operations,risks related to our ability to effectively transfer knowledge during this period of transition, and those risks and uncertainties identifiedin our Annual Report on Form 20-F for the year ended 31 December 2022 and our subsequent filings with the SEC. The forward-lookingstatements contained herein are based on management’s current expectations and beliefs and speak only as of the date hereof, andGalapagos makes no commitment to update or publicly release any revisions to forward-looking statements in order to reflectnew information or subsequent events, circumstances or changes in expectations, unless specifically required bylaw or regulation.

^1^ Throughout this press release, ‘Dr. Paul Stoffels’ should be read as ‘Dr. Paul Stoffels, acting via Stoffels IMC BV’